ISLB OÜ

What ISLB OÜ does

ISLB OÜ (legal name: International Society of Liquid Biopsy) is a nonprofit professional association founded in 2017 in Granada, Spain, registered in the Spanish National Registry of Associations (nº 612859, tax ID G19630953). It is the first international professional organization dedicated exclusively to liquid biopsy, a diagnostic approach that analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and other biomarkers from blood samples to support cancer diagnosis, treatment monitoring, and minimal residual disease tracking. The society serves oncologists, pathologists, cancer researchers, medical students and fellows, patient advocates, and industry partners across more than seven membership tiers, with reduced-fee pricing for LIC/LMIC/UMIC economies.

ISLB operates a portfolio of scientific dissemination and education products. Its flagship is the Annual Congress of Liquid Biopsy (8th edition scheduled for November 7-9, 2026 in Madrid, Spain), managed in partnership with International Conference Services (ICS) from Vancouver. The society publishes two official journals: The Journal of Liquid Biopsy (launched 2023, open-access, published by Elsevier, with Prof. Umberto Malapelle as Editor-in-Chief) and Critical Reviews in Oncology/Hematology. The Certificate of Advanced Studies (CAS) in Precision Medicine, a six-module online educational program launching in 2026, extends the society's product surface into structured credentialed education. Supporting infrastructure includes the Virtual Library (on-demand congress recordings), a webinar series, and three grant/award programs (Garcia-Puche $25,000 Innovation Grant, Rabab Gaafar Young Investigator Grant, $500 Travel Awards). Governance is handled by an elected Executive Committee (2025-2029 term) supported by seven functional committees.

Revenue is generated through membership dues, annual congress registration, CAS program fees, donations, and endorsement fees for third-party meetings and webinars. Distribution relies on the society's website (islb.info), social channels (LinkedIn, X, Facebook, YouTube, Bluesky), the annual congress, and a strategic alliance network including FNIH Biomarkers Consortium, BloodPAC, the European Liquid Biopsy Society, Friends of Cancer Research, Cancer-ID, MDIC, NIBSC, and Elsevier. No revenue figures, headcount, or external funding rounds are disclosed.

Name

ISLB OÜ

Legal name

INTERNATIONAL SOCIETY OF LIQUID BIOPSY

Website

https://islb.info

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

The International Society of Liquid Biopsy (ISLB) is a nonprofit professional association founded in 2017 that connects oncologists, pathologists, researchers, students, and industry through its annual congress, two scientific journals, online education programs, and grants dedicated to advancing liquid biopsy in cancer care.

Ownership category

akta.pro rank

Product category

Professional Medical Association (Liquid Biopsy)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000)

akta.pro primary industry

Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Knowledge Management & Scientific Collaboration / Literature Intelligence (HLAGAJAN)

Keywords

• Liquid biopsy association
• Precision oncology society
• Medical professional membership
• Clinical congress events
• Oncology continuing education

Headquarters

HQ city

Granada

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Dues: Annual membership fees with different categories including Regular, Associate, Affiliate, Student, Patient Advocate, Industry, and Emeritus memberships. Different pricing tiers exist for LIC/LMIC/UMIC countries.
2. Annual Congress Registration: Registration fees for the Annual Congress of Liquid Biopsy, with early bird discounts and standard rates. The 8th Annual Congress ISLB 2026 will be held in Madrid, Spain.
3. CAS Program Fees: Course fees for the Certificate of Advanced Studies in Precision Medicine. Grants are available to offset costs for eligible participants.
4. Donations: Accepts donations to support liquid biopsy implementation in clinical practice and fund research, education, and collaboration initiatives.
5. Endorsed Meetings: Endorsement fees for meetings and webinars that meet ISLB's multidisciplinary educational criteria.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

Core offering

ISLB OÜ is a nonprofit international professional society dedicated to advancing liquid biopsy in oncology. It sells individual memberships across multiple tiers, an annual international congress, two peer-reviewed scientific publications, a Certificate of Advanced Studies in Precision Medicine in partnership with the University of Granada, and a Virtual Library of educational content, all targeted at clinicians, researchers, students, and industry professionals in the liquid biopsy field.

Product overview

ISLB OÜ operates as a professional society offering a portfolio of products and services centered on liquid biopsy research and education. The core offerings include the ISLB Annual Congress (the only global congress dedicated exclusively to liquid biopsy), two official journals (The Journal of Liquid Biopsy and Critical Reviews in Oncology/Hematology), the Certificate of Advanced Studies in Precision Medicine (a 6-module online educational program), and a Virtual Library for on-demand content. Additional offerings include various grants and awards (Rabab Gaafar Young Investigator Grant, Garcia-Puche Grant, Travel Awards) and membership programs. The society connects healthcare professionals, mainly oncologists, to advance liquid biopsy implementation in clinical practice.

Differentiator

Problem solved

Functional benefit

Brands

• ISLB Annual Congress: Annual international congress dedicated exclusively to liquid biopsy research and clinical applications
• The Journal of Liquid Biopsy
• Virtual Library
• Garcia-Puche Grant
• Rabab Gaafar Young Investigator Grant
• Certificate of Advanced Studies (CAS) in Precision Medicine

Products and services

• ISLB Annual Congress The society's flagship annual international meeting bringing together clinicians, researchers, and industry to present and discuss advances in liquid biopsy. Next edition: 8th Annual Congress ISLB 2026, Madrid, March 26-28, 2026.
• Journal of Liquid Biopsy Peer-reviewed scientific journal published in partnership with Elsevier, dedicated to liquid biopsy research for members and the broader oncology research community.
• Critical Reviews in Oncology/Hematology (CROH) Peer-reviewed review journal associated with the society, covering critical reviews across oncology and hematology including liquid biopsy topics, in partnership with Elsevier.
• Certificate of Advanced Studies (CAS) in Precision Medicine Credentialed academic program in Precision Medicine offered jointly with the University of Granada, providing structured training for clinicians and researchers in liquid biopsy and precision oncology.
• ISLB Membership Annual individual membership across seven tiers — Regular, Associate, Affiliate, Student, Patient Advocate, Industry, and Emeritus — with pricing differentiated by World Bank country income classification.
• ISLB Virtual Library Online digital library hosting endorsed and curated liquid biopsy content, accessible to the ISLB membership and broader community.
• Rabab Gaafar Young Investigator Grant Competitive research grant awarded by ISLB to support young investigators conducting liquid biopsy research.
• Garcia-Puche Grant for Innovation in Liquid Biopsy Competitive grant awarded by ISLB recognizing innovation in liquid biopsy research.
• ISLB Travel Awards Competitive travel awards supporting eligible members and trainees to attend the ISLB Annual Congress.

Quantifiable outcome

• 8th Annual Congress 2026
• +1 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Nine partnerships are on record, tiered core.

• ElseviercoreStrategic or Co-development Partner · 1 November 2023Publisher partnership for The Journal of Liquid Biopsy, the first open-access journal exclusively dedicated to liquid biopsy research, published by Elsevier.
• Biomarkers Consortium (FNIH)coreStrategic or Co-development PartnerPartnership with the Foundation for the National Institutes of Health Biomarkers Consortium, a major initiative focused on advancing biomarkers for biomedical research and medicine development.
• BloodPACcoreStrategic or Co-development PartnerCollaboration with BloodPAC (Blood Profiling Atlas in Cancer), an initiative working to accelerate liquid biopsy research through standardized protocols and data sharing.
• European Liquid Biopsy Society (ELBS)coreStrategic or Co-development PartnerPartnership with the European Liquid Biopsy Society, another key organization in the field of liquid biopsy research and implementation in Europe.
• Friends of Cancer ResearchcoreStrategic or Co-development PartnerCollaboration with Friends of Cancer Research, an organization dedicated to science-driven policy and research approaches to benefit cancer patients.
• Cancer-IDcoreStrategic or Co-development PartnerPartnership with Cancer-ID, a European consortium focused on cancer biomarker identification and validation using liquid biopsy approaches.
• Medical Device Innovation Consortium (MDIC)coreStrategic or Co-development PartnerCollaboration with MDIC, a non-profit organization that works to advance medical device regulatory science and accelerate innovation for patients.
• NIBSC (National Institute for Biological Standards and Control)coreStrategic or Co-development PartnerPartnership with NIBSC, a UK regulatory authority that plays a key role in assuring the quality of biological medicines through standardization and reference materials.
• International Conference Services (ICS)coreImplementation/ SI/ Consulting PartnerConference management partner providing secretariat support for ISLB's annual congress and association management services. ICS manages registration, logistics, and event operations from their Vancouver, BC office.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• European Liquid Biopsy Society (ELBS): European counterpart professional society also focused on liquid biopsy research and clinical implementation. ISLB lists ELBS as a core strategic partner, indicating highly comparable mission, membership model, and stakeholder base in the same niche.
• Association for Molecular Pathology (AMP): Professional association for molecular pathologists and diagnostics, with overlapping audience on liquid biopsy assay validation and clinical reporting. AMP's molecular pathology focus overlaps directly with ISLB's quality-control and biomarker standardization work.
• Friends of Cancer Research: US-based research and policy collaboration organization that ISLB lists as a core partner. Operates in the same policy/standards-setting space for liquid biopsy and oncology biomarkers, sharing many sponsors and stakeholders.
• Blood Profiling Atlas in Cancer (BloodPAC): Public-private consortium accelerating liquid biopsy through data sharing and standards, listed as a core ISLB partner. Operates a different structural model (consortium vs. society) but pursues a directly overlapping mission around liquid biopsy in oncology.
• International Association for the Study of Lung Cancer (IASLC): Global multidisciplinary society dedicated to lung cancer, including significant coverage of liquid biopsy applications. Several ISLB leaders (e.g., Gandara) are past IASLC presidents, and the organizations overlap heavily in thoracic oncology membership and content.

Regional players

• Chinese Society of Clinical Oncology (CSCO): China's leading clinical oncology society with growing liquid biopsy programming. Geographic and language focus differs from ISLB, but the membership-congress-publication model and oncology biomarker focus are directly comparable.

Broad incumbents

• European Society for Medical Oncology (ESMO): Leading European clinical oncology society with growing emphasis on molecular diagnostics and liquid biopsy. Operates a similar membership-congress-journal model but across all oncology, making it the closest broad European incumbent peer.
• American Association for Cancer Research (AACR): Large incumbent scientific society covering all of cancer research, with multiple liquid-biopsy-focused sessions, journals, and task forces. AACR competes for ISLB's potential attendees and industry sponsors via broader scope and longer track record.
• American Society of Clinical Oncology (ASCO): Largest clinical oncology professional society globally, with extensive programming on liquid biopsy in diagnosis and treatment monitoring. ASCO absorbs much of the clinical-practice education demand that ISLB targets, but as part of a much broader portfolio.
• European Association for Cancer Research (EACR): European research-oriented cancer society that ISLB directly endorses meetings with (e.g., EACR 2025). Comparable membership-and-congress model and overlapping basic-translational research audience, though broader in scope than liquid biopsy alone.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights1 record

Customer concentration

• Xtwitter.com/isliquidbiopsy
• YouTubeyoutube.com/channel/UCPalUwasMnU2yY_DH18w8EQ
• Facebookfacebook.com/isliquidbiopsy
• LinkedInlinkedin.com/company/international-society-of-liquid-biopsy

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ISLB OÜ